Invited presentation followed by panel discussion on the next wave of innovation in immunotherapy of cancer: Paul Peter Tak, M.D., Ph.D., ...

Future Market Insights (FMI), a premier market research and consulting firm, today announced the publication of its latest ...

Recent Investor Day highlighted how AXPAXLI™ is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

In reviewing the current state of evidence, several points stand out. The strongest findings show that low doses of ketamine ...

A global analysis of 125 turmeric supplements across five major markets revealed widespread inconsistencies in labeling, ...

A malaria test commonly used across Asia and South America “is not fit for purpose”, researchers have claimed.

Good afternoon, and welcome to Sarepta's Third Quarter 2025 Financial Results Conference Call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, ...

Prior authorizations (PAs) continue to be one of the biggest hurdles to timely patient care. A recent survey found that 93% of physicians say that the PA process can delay treatment and three-quarters ...

First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session ...

Qure (QURE) shares drop after FDA questions AMT-130 data for Huntington’s disease, delaying BLA submission. Read more here.